SCHEMBL25256973

SCHEMBL25256973

CC(C)(C)OC(=O)Nc1ccc(-c2ccc(F)cc2)cc1NC(=O)c1ccc(S(=N)(=O)c2cncnc2)cc1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP17A1 P05093 2/20 0.45
HDAC1 Q13547 2/20 0.40
KCNQ4 P56696 1/20 0.38
KCNQ5 Q9NR82 1/20 0.38
HDAC2 Q92769 1/20 0.37
KDM4E B2RXH2 2/20 0.37
ALDH1A1 P00352 2/20 0.37
KMT2A Q03164 2/20 0.37
LMNA P02545 1/20 0.37
MAPT P10636 1/20 0.37
HPGD P15428 1/20 0.37
NAMPT P43490 1/20 0.37
RORC P51449 3/20 0.37
MMP8 P22894 4/20 0.37
MMP3 P08254 2/20 0.37
HSD17B10 Q99714 1/20 0.37
ABCB1 P08183 1/20 0.36
EGFR P00533 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25214971 0.93 CYP17A1 (0.46) CYP17A1HDAC1KCNQ4KCNQ5HDAC2
SCHEMBL25250114 0.92 CYP17A1 (0.44) CYP17A1HDAC1KCNQ4KCNQ5HDAC2
SCHEMBL30474730 0.92 CYP17A1 (0.44) CYP17A1HDAC1KCNQ4KCNQ5HDAC2
SCHEMBL25254704 0.91 CYP17A1 (0.53) CYP17A1HDAC1KCNQ4KCNQ5HDAC2
SCHEMBL30474840 0.91 HDAC1 (0.46) CYP17A1HDAC1KMT2ANAMPTABCB1
SCHEMBL30474745 0.91 CYP17A1 (0.43) CYP17A1HDAC1KCNQ4KCNQ5HDAC2
SCHEMBL25255018 0.91 HDAC1 (0.46) CYP17A1HDAC1KMT2ANAMPTABCB1
SCHEMBL25214617 0.91 CYP17A1 (0.43) CYP17A1HDAC1KCNQ4KCNQ5HDAC2
SCHEMBL25251162 0.90 CYP17A1 (0.42) CYP17A1HDAC1KCNQ4KCNQ5HDAC2
SCHEMBL25247346 0.90 CYP17A1 (0.43) CYP17A1HDAC1KCNQ4KCNQ5HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250136570-A1 HDAC INHIBITORS AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. 2025-05-01 US disclosed
EP-4441033-A1 NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF Tango Therapeutics, Inc. (US) 2024-10-09 EP disclosed
US-12043607-B2 HDAC inhibitors and therapeutic use thereof TANGO THERAPEUTICS, INC. (US) 2024-07-23 US disclosed
US-12043607-B2 HDAC inhibitors and therapeutic use thereof TANGO THERAPEUTICS, INC. (US) 2024-07-23 US disclosed
US-12043607-B2 HDAC inhibitors and therapeutic use thereof TANGO THERAPEUTICS, INC. (US) 2024-07-23 US disclosed
WO-2023102162-A1 TGONOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. (US) 2023-06-08 WO disclosed
US-20230174501-A1 NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. 2023-06-08 US disclosed
US-20230174501-A1 NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. 2023-06-08 US disclosed
US-20230174501-A1 NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. 2023-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230174501-A1 NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF HDAC1, HDAC7, HDAC5 CYP17A1 1294/4885HDAC1 1/4885KCNQ4 4641/4885
US-20250136570-A1 HDAC INHIBITORS AND THERAPEUTIC USE THEREOF HDAC1, HDAC7, HDAC5 CYP17A1 657/4885HDAC1 1/4885KCNQ4 4646/4885
US-12043607-B2 HDAC inhibitors and therapeutic use thereof HDAC1, HDAC7, HDAC5 CYP17A1 657/4885HDAC1 1/4885KCNQ4 4646/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.